ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 836

Clinical Responses and Patient Reported Outcomes to NNC0109-0012 (anti-IL-20 mAb) in Rheumatoid  Arthritis (RA) Patients Following 12-Weeks Dosing and 13 Weeks Follow up: Results From a Phase 2a Trial

Ladislav ŠEnolt1, Marie Göthberg2, Xavier Valencia3 and Eva Dokoupilova4, 1Institute of Rheumatology, Prague, Czech Republic, 2Biostatistics, Novo Nordisk, A/S, Soeborg, Denmark, 3Clinical Medical and Regulatory Affairs, Novo Nordisk, Inc., Princeton, NJ, 4Medical Plus s.r.o, Uherske Hradiste, Czech Republic

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Antibodies, clinical trials, interleukins (IL) and rheumatoid arthritis, treatment

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy and Safety of Novel Entities

Session Type: Abstract Submissions (ACR)

Background/Purpose: NNC0109-0012 (anti-IL-20 mAb) is a novel human monoclonal IgG4 antibody which binds to and neutralizes the activity of IL-20. Data from a phase 1 single-dose trial in healthy volunteers and RA patients, and a multiple-dose trial in RA patients, did not raise any safety concerns. NNC0109-0012 has linear pharmacokinetics in the investigated dose range (1-3 mg/kg) and signs of reduced disease activity were shown in RA patients. Objectives of this phase 2a trial were to evaluate changes in disease activity in RA patients with active disease using the following endpoints: DAS28-CRP, ACR20/50/70, and the patient-reported outcomes physical function (HAQ-DI), pain (Pain VAS) and global disease activity (PtGA VAS) after 12 weeks of treatment and during a 13-week follow up period.

Methods: A total of 67 RA patients (51 females:16 males) with active disease (DAS28 (CRP) >4.5, ≥5 swollen and ≥5 tender joints) were randomized in a 2:1 ratio (45 NNC0109-0012: 22 placebo) in a multicenter, double-blind, placebo-controlled, parallel group trial. Patients were dosed once-weekly s.c. with 3 mg/kg NNC0109-0012 or placebo for 12 weeks and followed for an additional 13 weeks. Patients were 18 to 75 years old with active RA and on stable methotrexate (MTX) treatment (>7.5 to <25 mg/week for at least 4 weeks). The primary endpoint was change in DAS28 (CRP) at Week 12.

Results: DAS28 (CRP) was significantly decreased compared to placebo at Weeks 12 and 16, and through Weeks 12 – 25 for seropositive (RF and anti-CCP positive) patients (n=29 and 14; 3 mg/kg and placebo, respectively). Significantly more NNC0109-0012 treated seropositive patients compared to placebo achieved ACR20/50 at Week 12 and ACR70 at Weeks 12, 16 and 20. Physical function, pain and global disease activity were significantly improved compared to placebo for seropositive patients for Weeks 12 – 25. Similar trends in NNC0109-0012 effects on most of the secondary endpoints for disease activity were observed in all randomized patients, although not all changes were significant. No deaths, serious adverse events or dose limiting toxicities were reported.

 

 

Week 12

Week 16

Week 20

Week 25

DAS28 (CRP)a

-0.88*

-0.72*

-0.51

-0.60

DAS28 (CRP), S+

-1.66†

-1.55†

-1.26**

-1.24**

ACR20 (%), S+

58.6/21.4*

62.1/35.7

58.6/28.6*

58.6/35.7

ACR50 (%), S+

48.3/14.3*

44.8/14.3

44.8/21.4

44.8/21.4

ACR70 (%), S+

34.5/0*

34.5/0*

31.0/0*

31.0/7.1

HAQ-DI, S+

-0.45*

-0.32

-0.42*

-0.47*

Pain (VAS), S+

-30†

-28**

-25**

-29†

PtGA (VAS), S+

-28†

-29†

-25**

-28†

DAS28 (CRP), HAQ-DI, pain (VAS), PtGA (VAS) shown as mean difference for NNC0109-0012 ˗ placebo; Proportion with ACR20/50/70 for NNC or placebo shown as NNC/placebo.             VAS = visual analogue scale (mm).  aAll randomized patients ;                                  S+=seropositive ; * = p<0.05, ** = p<0.01,†= p<0.001

 Conclusion: This phase 2a trial investigating NNC0109-0012 (anti-IL-20 mAb) in patients with RA met its primary endpoint, showing significant improvement in DAS28 (CRP) after 12 weeks. For the sub-group of RF/anti-CCP-positive patients, the treatment effects of NNC0109-0012 on all disease parameters were significantly larger than for all randomized patients at week 12 and were sustained during the 13 weeks after stopping study drug administration. Treatment with NNC0109-0012 revealed no safety concerns. The data from this trial support further clinical development of NNC0109-0012 (anti-IL-20 mAb) in RA.


Disclosure:

L. ŠEnolt,
None;

M. Göthberg,

Novo Nordisk ,

3;

X. Valencia,

Novo Nordisk, Inc,

3;

E. Dokoupilova,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-responses-and-patient-reported-outcomes-to-nnc0109-0012-anti-il-20-mab-in-rheumatoid-arthritis-ra-patients-following-12-weeks-dosing-and-13-weeks-follow-up-results-from-a-phase-2a/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.